VRTX
Vertex Pharmaceuticals Inc / Ma
$485.39
-11.11 (-2.24%)
At close · Jul 10
Market Cap
$123.19B
Shares
253,805,417
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-09-30 | — | |
| 8-K | 2026-07-07 | 2026-07-06 | |
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-05-13 | — | |
| 10-Q | 2026-05-05 | 2026-03-31 | |
| 8-K | 2026-05-04 | — | |
| 8-K | 2026-04-29 | 2026-04-28 | |
| DEF 14A | 2026-04-02 | 2026-05-13 | |
| Investor Event Transcript | 2026-03-31 | — | |
| 8-K | 2026-03-31 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| 10-K | 2026-02-13 | 2025-12-31 | |
| 8-K | 2026-02-12 | — | |
| 10-Q | 2025-11-04 | 2025-09-30 | |
| 8-K | 2025-11-03 | — | |
| 10-Q | 2025-08-05 | 2025-06-30 | |
| 8-K | 2025-08-04 | — | |
| 8-K | 2025-05-19 | — | |
| 8-K | 2025-05-14 | — | |
| 10-Q | 2025-05-06 | 2025-03-31 | |
| 8-K | 2025-05-05 | — | |
| DEF 14A | 2025-04-03 | 2025-05-14 | |
| 8-K | 2025-03-28 | — | |
| 10-K | 2025-02-13 | 2024-12-31 | |
| 8-K | 2025-02-10 | 2025-02-04 | |
| 8-K | 2024-12-20 | — | |
| 10-Q | 2024-11-05 | 2024-09-30 | |
| 8-K | 2024-11-04 | — | |
| 8-K | 2024-08-16 | 2024-08-15 | |
| 10-Q | 2024-08-02 | 2024-06-30 | |
| 8-K | 2024-08-01 | — | |
| 8-K | 2024-06-27 | — | |
| 8-K | 2024-05-20 | — | |
| 8-K | 2024-05-15 | — | |
| 10-Q | 2024-05-07 | 2024-03-31 | |
| 8-K | 2024-05-06 | — | |
| 8-K | 2024-04-11 | 2024-04-10 | |
| DEF 14A | 2024-04-04 | 2023-05-15 | |
| 10-K | 2024-02-15 | 2023-12-31 | |
| 8-K | 2024-02-05 | — | |
| 8-K | 2023-12-08 | — | |
| 8-K | 2023-12-05 | — | |
| 10-Q | 2023-11-07 | 2023-09-30 | |
| 8-K | 2023-11-06 | — | |
| 8-K | 2023-10-05 | 2023-10-03 | |
| 10-Q | 2023-08-02 | 2023-06-30 | |
| 8-K | 2023-08-01 | — | |
| 8-K | 2023-05-18 | 2023-05-17 |
Showing 1–50 of 93 filings
Key facts
CIK
875320
CUSIP
92532F100
13F (30d)
127 filings
85 filers
Visit website
Investor relations